Navigating the challenge of patient selection and scales to measure outcomes in ketamine trials for treatment-resistant depression.
Journal of psychopharmacology (Oxford, England) – January 01, 2025
Source: PubMed
Summary
Ketamine offers new hope for patients with treatment-resistant depression (TRD), but measuring its effectiveness requires careful consideration. Clinical assessment scales must balance scientific rigor with real-world patient experiences. Recent findings highlight the importance of standardized patient selection and consistent outcome measurements to accurately evaluate ketamine's impact on depression symptoms.
Abstract
The letter about the article "Ketamine for treatment-resistant major depressive disorder: Double-blind active-controlled crossover study" that discusses some points about methodology, outcome measures, and results.